dr. debu tripathy on the cdk4/6 inhibitor pd 0332991 in er-positive advanced breast cancer
Published 11 years ago • 450 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:47
dr. tripathy on combination strategies with cdk4/6 inhibitors in breast cancer
-
1:21
dr. tripathy on combination strategies with cdk4/6 inhibitors in hr breast cancer
-
0:22
copy of dr. tripathy on combination strategies with cdk4/6 inhibitors in hr breast cancer
-
1:40
debu tripathy, md, regarding cdk 4/6 inhibitors in the treatment of breast cancer
-
2:55
debu tripathy, md, introduces new information oncdk4/6 inhibitors discussed at asco20
-
1:18
debu tripathy, md on the importance of cdk4/6 for future breast cancer treatments
-
0:50
debu tripathy on hormone therapy compliance in patients with breast cancer
-
3:26
updates in er-positive breast cancer by debu tripathy, md
-
8:07
the history of breast cancer diagnosis, subtypes and treatment
-
10:02
diagnosing microinvasive breast cancer in a background of intraductal carcinoma
-
7:13
the biological rationale for cdk4/6 inhibitors
-
1:22
dr. debu tripathy gives an overview of targeted therapies for breast cancer
-
3:50
cdk4/6 inhibitors in metastatic breast cancer
-
1:25
dr. debu tripathy on 10 versus 5 years of adjuvant tamoxifen
-
4:24
new concepts in cdk4/6 inhibitor therapy for breast cancer
-
1:09
dr. debu tripathy on molecular predictors of outcome in breast cancer
-
2:04
dr. richard finn discusses palbociclib for patients with advanced breast cancer
-
3:27
metastatic breast cancer: cdk4/6 inhibitors
-
1:25
dr. debu tripathy reviews the phase iii confirm trial
-
1:35
dr. richard finn on the rationale for targeting cdk4/6 with pd 0332991
-
1:19
debu tripathy on hormonal therapy for breast cancer
-
2:24
dr. tripathy on genomically guided therapy in breast cancer